MEI Pharma has issued a reminder to its shareholders to vote in favor of its pending transaction with Infinity Pharmaceuticals. Independent proxy advisory firms ISS and Glass Lewis have recommended a vote in favor of the transaction, recognizing the strategic benefits of the combination. MEI shareholders have the opportunity to participate in a well-capitalized company with a diversified pipeline of three clinical-stage programs. Voting in favor of the transaction allows for potential value creation and access to the expertise of both MEI and Infinity in cancer treatment development.
MEI Pharma, Inc. (NASDAQ: MEIP) (the “Company”) today reminded shareholders to vote FOR the Company’s pending transaction with Infinity Pharmaceuticals Inc. (Nasdaq: INFI) (“Infinity”) in connection with the upcoming special meeting on July 14, 2023.
MEI issued the following statement:
With the special meeting just days away, now is the time for MEI shareholders to vote FOR our pending Infinity transaction.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
As a reminder, Independent leading proxy advisory firms, ISS and Glass Lewis, both recommend that MEI shareholders vote FOR the Infinity transaction. In making their recommendations, both ISS and Glass Lewis recognize the strategic benefits of our combination with Infinity.
MEI shareholders have an opportunity to participate in the upside potential of a combined company that is well capitalized and positioned to advance a diversified pipeline of three clinical-stage development programs.
A vote FOR the transaction is a vote FOR:
- Creating a diversified pipeline of three clinical-stage development programs that have the potential, in combination with current therapies, to overcome known resistance mechanisms.
- Providing potential opportunities for near-term value creation from upcoming data that is expected to be released over the next approximate 6-24 months.
- Benefiting from the clinical development and regulatory expertise of the MEI and Infinity teams in developing pharmaceutical products to treat cancer.
Don’t miss out. We encourage you to vote today FOR the transaction and enable our combined company to be well positioned to create value for shareholders and deliver improved therapeutic options for patients.
YOUR VOTE IS IMPORTANT!
VOTE “FOR” THE TRANSACTION WITH INFINITY PHARMACEUTICALS TODAY
MEI Pharma has scheduled the special meeting to approve the proposed transaction with Infinity on July 14, 2023. All shareholders of record as of the close of business on May 24, 2023 are entitled to vote at the special meeting.
Shareholders who have questions or need assistance voting your shares, please contact Alliance Advisors, MEI’s proxy solicitor:
Source: BioSpace